Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) Single-Dose Vial 2 mL (RX)

Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) is an FDA-approved, cutting-edge antineoplastic agent used in the treatment of metastatic breast cancer and unresectable or metastatic liposarcoma. This single-dose, sterile, 2 mL vial delivers precise dosing and reliable administration in hospital, infusion center, and oncology clinic settings. Eribulin Mesylate is a synthetic analog of halichondrin B, proven to extend survival in patients with advanced or treatment-resistant cancer.

Advanced Chemotherapy for Metastatic Breast Cancer & Liposarcoma

Uses:

Eribulin Mesylate Injection is indicated for:

• Metastatic Breast Cancer: In patients who have previously received at least two chemotherapy regimens for late-stage disease, including an anthracycline and a taxane (unless contraindicated).
• Unresectable or Metastatic Liposarcoma: In adults who have received prior anthracycline-containing chemotherapy.

For Intravenous Infusion Only: Not for intramuscular, subcutaneous, or oral administration. Must be diluted and administered under healthcare professional supervision.

Mechanism of Action

Eribulin is a microtubule dynamics inhibitor—it blocks cancer cell growth and division, helping reduce tumor size and slow cancer progression. As a non-taxane microtubule inhibitor, it offers an alternative for patients resistant to conventional chemotherapy.

Common Side Effects:

• Neutropenia (low white cell count)/leukopenia: Risk of infection
• Anemia, thrombocytopenia: Fatigue or bruising
• Peripheral Neuropathy: Tingling, numbness, or pain in hands and feet
• Hair loss (alopecia), constipation, nausea, vomiting
• Fatigue, fever, muscle pain (myalgia)

Serious Side Effects:

• Severe neutropenia or febrile neutropenia (potentially life-threatening infections)
• QT interval prolongation and heart rhythm disturbances
• Liver dysfunction and increased liver enzymes
• Severe allergic/anaphylactic reactions

Important: Regular monitoring of blood cell counts, liver function, and heart (ECG) is required during therapy.

Contraindications:

• Hypersensitivity to Eribulin or components
• Pregnancy and breastfeeding (Category D: may cause fetal harm)

CDC and Chemotherapy Safety Guidelines:

According to CDC and OSHA guidelines for chemotherapy agents:

• Eribulin Mesylate Injection must be administered only by trained healthcare providers, in certified facilities.
• Strict adherence to cytotoxic drug handling (PPE, negative pressure rooms, closed-system drug-transfer devices).
• Double-check dosage & patient identity before administration.
• Dispose of used vials and materials as hazardous medical waste in accordance with federal and local regulations.
• Pregnant or breastfeeding staff should not prepare or handle eribulin injections.
• Monitor patients for infusion reactions and cytopenias per protocol.
• Provide pre-treatment and ongoing patient education for symptom and infection reporting.

Always consult institutional protocols and CDC Safe Handling of Hazardous Drugs for full safety guidance.

Why Choose Eribulin Mesylate Injection?

• Clinically proven to prolong overall survival in advanced cancer
• Uniform dosing: 1 mg/2 mL single-dose vial simplifies preparation
• Sterile, ready-to-use packaging for oncology pharmacy safety
• Optimized for hospital, infusion center, and oncology clinic protocols
• Supported by NCCN, ASCO, ESMO, and CDC guidelines

Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL): Advanced, Targeted Cancer Care

Order today for hospital and oncology pharmacy use—empower your fight against advanced breast cancer and liposarcoma with the most trusted, safety-optimized injectable chemotherapy!